Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanHKSE:02268 +1.86%50 Pretax Margin % is 26.81% as of Dec. 2025, which is 6% above its 10-year median of 25.36. GuruFocus rates HKSE:02268 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 95.07% on this metric.
The historical rank and industry rank for WuXi XDC Cayman's Pretax Margin % or its related term are showing as below:
HKSE:02268'
s Pretax Margin % Range Over the Past 10 Years
Min: 16.93 Med: 25.36 Max: 33.59
Current: 26.43
HKSE:02268's Pretax Margin % is ranked better than 95.07% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.55
vs HKSE:02268: 26.43
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
WuXi XDC Cayman Pretax Margin % Related Terms
WuXi XDC Cayman Pretax Margin % Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02268 vs TMO, DHR, NTRA: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, WuXi XDC Cayman's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman (HKSE:02268) has a Pretax Margin % of 26.81% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on WuXi XDC Cayman and its competitors. This is near median its historical median of 25.36. Over the past decade, WuXi XDC Cayman's Pretax Margin % has ranged from 16.93 to 33.59. According to the industry distribution chart, WuXi XDC Cayman ranks #10 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 4.9%.
Is WuXi XDC Cayman's Pretax Margin % too high?
WuXi XDC Cayman's current Pretax Margin % of 26.81% is near median its 10-year median of 25.36. Over the past 10 years, this metric has ranged from a low of 16.93 to a high of 33.59. Based on the distribution chart, WuXi XDC Cayman ranks #10 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #10 out of 203 companies for Pretax Margin %. This places WuXi XDC Cayman in the top 5% of its industry — outperforming the majority of peers. Historically, WuXi XDC Cayman's own Pretax Margin % has ranged from 16.93 to 33.59 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on WuXi XDC Cayman and its competitors. WuXi XDC Cayman's current Pretax Margin % is 26.81%, which is near median its own 10-year median of 25.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (HKSE:02268) has a current Pretax Margin % of 26.81%. The current Pretax Margin % is 26.81%, which is near median its 10-year median of 25.36. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For WuXi XDC Cayman (HKSE:02268), the current Pretax Margin % is 26.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for HKSE:02268
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02268 has been successfully added to your 
